Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis

K S Ginsburg1, M H Liang, L Newcomer

  • 1Department of Rheumatology and Immunology, Brigham and Women's Hospital, Boston, MA 02115.

Annals of Internal Medicine
|December 15, 1992
PubMed

Insights

Elevated anticardiolipin antibodies are a significant risk factor for venous thrombosis and pulmonary embolism in men. However, anticardiolipin antibodies do not appear to increase the risk of ischemic stroke in this population.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Immunology

Background:

  • Anticardiolipin antibodies (aCL) are associated with an increased risk of thrombosis.
  • The role of aCL as a risk factor for specific thrombotic events like ischemic stroke and venous thromboembolism (VTE) requires further elucidation in healthy populations.

Purpose of the Study:

  • To investigate whether anticardiolipin antibodies are a risk factor for ischemic stroke and venous thrombosis in healthy adult men.

Main Methods:

  • A nested case-control study was conducted within the prospective Physicians' Health Study cohort.
  • Plasma samples from 22,071 male physicians were analyzed for IgG anticardiolipin antibodies using ELISA.
  • Conditional logistic regression was used to calculate relative risks for VTE and ischemic stroke based on aCL antibody titers.

Main Results:

  • Higher anticardiolipin antibody titers were observed in patients with deep venous thrombosis or pulmonary embolism compared to controls (P=0.01).
  • Individuals with aCL antibody titers above the 95th percentile had a 5.3-fold increased risk of developing deep venous thrombosis or pulmonary embolism (P=0.01).
  • No significant difference in aCL antibody titers was found between patients with ischemic stroke and controls, indicating no clear association.

Conclusions:

  • Anticardiolipin antibody levels above the 95th percentile are a significant risk factor for venous thromboembolism (deep venous thrombosis or pulmonary embolism) in healthy men.
  • Anticardiolipin antibodies are not identified as a risk factor for ischemic stroke in this cohort of healthy adult men.
Abstract

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.